The structural profiles are close, with Ionis Pharmaceuticals carrying a narrow edge on growth. Insmed still has the edge on growth, which keeps the comparison from looking entirely one-sided. On the market side, Ionis Pharmaceuticals is in better shape — its trend is intact while Insmed's trend has broken down. That puts structure and market broadly in agreement — Ionis Pharmaceuticals's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
The page question resolves through growth, where Insmed Incorporated holds the stronger read even though the broader score still favours Ionis Pharmaceuticals, Inc..
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. INSM and IONS share the same industry classification.
For a similarity-based comparison, see how Insmed and Ionis Pharmaceuticals each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
The structural gap is limited here, but current pricing still leans against Insmed Incorporated.
Valuation position uses peer-relative valuation score where available.
Where INSM and IONS each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The main growth separation is clear, driven by a meaningfully stronger expansion profile.
Market confirmation also leans toward Ionis Pharmaceuticals, Inc., which makes the lead look better backed by actual market behaviour.
The lead is built on both growth and valuation — though growth still provides a counterweight.
Break down the INSM vs IONS comparison across all dimensions with the full interactive tool.
Explore how INSM and IONS each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.